Jazz Pharmaceuticals announced the submission of a Marketing Authorization Application to the European Medicines Agency for solriamfetol, a selective dopamine and norepinephrine reuptake inhibitor, as a treatment to improve wakefulness and reduce excessive daytime sleepiness in adult patients with narcolepsy or obstructive sleep apnea.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.